

OFFICIALLY LICENSED

BEST OF ASCO®

2022 ANNUAL MEETING

CIUDAD DE MÉXICO



20 - 22
JULIO 2022

PROGRAMA

#cancerinfantil

#melanoma

#hepatocarcinoma

medicine.matters@medicalrp.com.mx

999 528 6415 ☎

#cancerderinon

Inscripciones abiertas:
congresosmpr.com.mx

#cancerdepancreas

#cancerdemama

797 ☎



COMITÉ CIENTÍFICO

Dra. Guadalupe Cervantes Sánchez
Dr. Pabel Miranda Aguirre

INVITADOS EXTRANJEROS

Lluch Ana.
Chavez Mc Gregor Mariana
Valero Vicente

Valencia, Esp.
Houston, Tx
Houston, Tx

COORDINADORES DE MÓDULOS

Aguayo González Álvaro
Alatorre Alexander Jorge
Calderillo Ruiz Germán
Cervantes Sánchez Guadalupe
Escobar Gómez Mario
Fariás Alarcón Miguel
Gurrola Machuca Héctor
Orta Cortes David
Salas Gonzalez Efraín
Suarez García David

INCMNSZ
INER
INCan
CMN 20 de Nov.
HGM
CMN 20 de Nov.
CMN 20 de Nov.
Hosp. Naval
Guadalajara, Jal.
León, Gto

FACULTATIVOS

Fernando Aldaco Sarvide
Miguel Ángel Álvarez Avitia
Pedro Arredondo Ruiz
Enrique Ávila Monteverde
Rocío Baltazar Contreras
Yolanda Bautista Aragón
Alan Barguete Torres
Yanin Chavarri Guerra
Guadalupe Díaz Alvarado
Adriana Domínguez ayala
Homero Fuentes de la Peña
Rocío del Carmen García Pérez
Ma. de la Luz García Tinoco
Gerogina Garnica Jaliffe
Martín Granados García
Alicia Gutiérrez Mata
Fabian Martínez Herrera
Pabel Miranda Aguirre
Mariana Miyagui
Brizio Moreno Jamie
Gabriela Nuñez Guardado
Rodrigo Riera Sala
Samuel Rivera Rivera
Vanessa Rosas Camargo
Omar Serrano Villamayor
Edwin Tejada Valerio
Adalberto Toriz Hernández
Rogelio Trejo Rosales
Hayde Verduso Aguirre
Cynthia Villareal

MIÉRCOLES 20 DE JULIO

8:45 Inauguración

Dr. Fernando Aldaco S, Dr. Rafael Medrano Guzman, Dr. Pabel Miranda Aguirre, Dra. Guadalupe Cervantes Sánchez

David Erazo Valle: Maestro de Ceremonias

GINECOLÓGICO

9:00 LBA5500 ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer.

Dra. Georgina Garnica Jaliffe

9:15 5509 Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study.

Dra. Rocío Baltazar Contreras

9:30 Mesa Redonda

Dr. Mario Escobar Gómez
Hos, Gral. SS

CÁNCER DE MAMA LOCAL

9:50 LBA 1003: Sobrevida Global en pacientes con CM RH+HER2- tratadas con Palbociclib+Letrozol

Dr. Juan Antonio Matus

10:35 LBA501 LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).

Dra. Adriana Domínguez Ayala

10:50 507 Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.

Dr. Fernando Aldaco Sarvide

11:05 506 Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.

Dr. Brizio Moreno Jaime

MIÉRCOLES 20 DE JULIO

11:20 Desde mi punto de vista

Dr. Vicente Valero

11:35 Mesa Redonda

Dra. Guadalupe Cervantes
Sánchez CMN 20 de Nov.

11:55 Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.

Dr. Brizio Moreno Jaime

12:40 **Coffe Break**

SISTEMA NERVIOSO CENTRAL

13:10 2010 Long-Term Control and Safety of Larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system tumors.

Dr. Rogelio Trejo Rosales

13:25 2001. Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).

Dr. Rodrigo Riera Sala

13:40 Mesa Redonda

Dra. Ana Martín Aguilar
CMN Siglo XXI

MISCELANES

14:00 2507. Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.

Dra. Vanessa Rosas Camargo

14:15 12000. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.

Dra. Hayde Verduzco Aguirre

14:30 12023. Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221.

Dra. Yanin Chavarri Guerra

14:45 Mesa Redonda

Dr. Alavaro Aguayo
INNSZ

15:05 **CIERRE DEL DÍA**

JUEVES 21 DE JULIO

8:00 Registro

PULMÓN

- 9:00 Nivolumab + chemotherapy (CT) vs CT as neoadjuvant treatment for resectable stage IIIA-B non-small cell lung cancer: NADIM II trial. Dr. Fabian Martinez Herrera
- 9:15 9002. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Dr. Omar Serrano Villamayor
- 9:30 Amivantamab and Lazertinib in patients with EGFR.mutant non small cell lung cancer after progression on osimertinib and platinum based chemotherapy: updated results from CHRYSALIS-2 Dr. Edwin Tejada Valerio
- 9:45 Mesa Redonda Dr. Jorge Alatorre Alexander INER
- 10:05 Estudio CROWN: Impacto de la Nueva Evidencia en el Manejo del Paciente con CPCNP ALK+ Dr. Jorge Alatorre

10:50 **Coffe Break**

CABEZA Y CUELLO

- 11:20 6015. Refining nodal category in TNM staging with extent of extranodal extension for oral cavity squamous cell carcinoma. Dr. Martín Granados García
- 11:35 6000. Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised phase III trial. Dra Gabriela Nuñez Guardado
- 11:50 6004. An open label non-inferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma Dr. Miguel Á. Álvarez Avitia
- 12:05 Mesa Redonda Dr Héctor Gurrola CMN 20 de Nov.

JUEVES 21 DE JULIO

12:20 Simposio

MELANOMA

13:05 LBA9500. Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study.

Dra. Rocio García Pérez

13:20 9505. Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047

Dra. Yolanda Bautista Aragón

13:35 9502. Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

Dra. Alicia Gutierrez Mata

13:50 Mesa Redonda

Dr. David Suárez García
IMSS León

CX ROBÓTICA

14:10 2696 A randomized no - inferiority trial of robotic versus open radical hysterectomy for early stage cervical cancer.

Dr. Enrique Ávila Monteverde

14:25 1327 Transoral robotic surgery TORS- guided radioterapia volumen de-intensification en p16 positivo unknown primary squamous cell carcinoma.

Dr. Pabel Miranda Aguirre

14:40 Mesa Redonda

Dr Miguel Farías
CMN 20 de Nov.

15:00 **CIERRE DEL DÍA**

VIERNES 22 DE JULIO

8:00 Registro

GASTRO INTESTINAL

- 9:00 LBA1. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC); results from the phase 3 PARADIGM trial. Dr. Alan Burquette
- 9:15 LBA100. Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial. Dr. Alan Burquette
- 9:30 LBA4011. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. Dra. Mariana Miyagui
- 9:45 4004. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211). Dra. Mariana Miyagui
- 10:00 Mesa Redonda Dr. Germán Calderillo
INCAN
- 10:20 Papel de los inhibidores de tirosina cinasa en el tratamiento de primera línea del Carcinoma Hepatocelular avanzado. Dra. Guadalupe Díaz Alvarado

11:05 **Coffe Break**

GENITO URINARIO

- 11:35 4513. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426. Dr. Samuel Rivera Rivera

VIERNES 22 DE JULIO

- 11:50 LBA5004. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
Dr. Pedro Arredondo Ruiz
- 12:05 4502 The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.
Dr. Adalberto Toriz Hernandez
- 12:20 Mesa Redonda
Dr. David Orta Cortes
Hosp. Naval
- MEMA METASTÁSICO**
- 12:40 SG como guía para las decisiones terapéuticas en pacientes con Ca. de mama RH+ HER2-
Dra. Mariana Chavez Mc Gregor
- 13:25 LBA3. Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study.
Dr. Homero Fuentes
- 13:40 LBA1001. Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician's Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer.
Dra. Cynthia Villarreal
- 13:55 LBA1004. A randomized phase II trial of fulvestrant or exemestane with or without Ribociclib after progression on Anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2 negative metastatic breast cancer (MBC): MAINTAIN trial.
Dra. Ma. de la Luz García
- 14:10 Desde mi punto de vista
Dra. Ana Lluch
- 14:25 Mesa Redonda
Dr. Efraín Salas
Gdl, Jal.
- 14:45 **CIERRE DEL DÍA**



El CMO está otorgando 18 puntos de recertificación para los asistentes de este evento.

